Literature DB >> 23110818

Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.

Dimitra Georgiadou1, Kostas Stamatakis, Eleni K Efthimiadou, George Kordas, Donald Gantz, Angeliki Chroni, Efstratios Stratikos.   

Abstract

Lipoprotein glomerulopathy (LPG) is a dominant inherited kidney disorder characterized by lipoprotein thrombi in glomerular capillaries. Single-amino-acid mutations in apoE have been associated with the development of the disease, although the mechanism is unknown. In an effort to gain mechanistic insight linking the presence of such mutations and the development of LPG, we evaluated the effects of three of the most common apoE3 variants associated with this disease, namely R145P(Sendai), R147P(Chicago), and R158P(Osaka or Kurashiki), on the structural and conformational integrity of the protein. All three variants were found to have significantly reduced helical content, to expose a larger portion of hydrophobic surface to the solvent, and to be significantly thermodynamically destabilized, often lacking functionally relevant unfolding intermediates. Furthermore, all variants were aggregation prone and had enhanced sensitivity to protease digestion. Finally, although the variants were able to form discoidal lipoprotein particles, discrete subpopulations of poorly formed or aberrant particles were evident. Furthermore, these lipoprotein particles were thermodynamically destabilized and aggregation prone. Overall, our data suggest that these mutations induce a generalized unfolding of the N-terminal domain of apoE3 toward a molten-globule-like structure. ApoE3 N-terminal domain unfolding due to mutation may constitute a common mechanism underlying the protein's association with the pathogenesis of LPG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110818      PMCID: PMC3520522          DOI: 10.1194/jlr.M030965

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  57 in total

1.  Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains.

Authors:  L P Aggerbeck; J R Wetterau; K H Weisgraber; C S Wu; F T Lindgren
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

2.  Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

Authors:  S Oikawa; A Matsunaga; T Saito; H Sato; T Seki; K Hoshi; K Hayasaka; H Kotake; H Midorikawa; A Sekikawa; S Hara; K Abe; T Toyota; H Jingami; H Nakamura; J Sasaki
Journal:  J Am Soc Nephrol       Date:  1997-05       Impact factor: 10.121

3.  Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain.

Authors:  D H Kim; H Iijima; K Goto; J Sakai; H Ishii; H J Kim; H Suzuki; H Kondo; S Saeki; T Yamamoto
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

Review 4.  Lipoprotein and receptor interactions in vivo.

Authors:  J Herz; T E Willnow
Journal:  Curr Opin Lipidol       Date:  1995-04       Impact factor: 4.776

5.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

6.  Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.

Authors:  C Wilson; M R Wardell; K H Weisgraber; R W Mahley; D A Agard
Journal:  Science       Date:  1991-06-28       Impact factor: 47.728

7.  Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins.

Authors:  E Hurt-Camejo; S Andersen; R Standal; B Rosengren; P Sartipy; E Stadberg; B Johansen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

8.  A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells.

Authors:  Y Huang; A von Eckardstein; S Wu; N Maeda; G Assmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall.

Authors:  H Shimano; J Ohsuga; M Shimada; Y Namba; T Gotoda; K Harada; M Katsuki; Y Yazaki; N Yamada
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation.

Authors:  M F Linton; J B Atkinson; S Fazio
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

View more
  16 in total

1.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

2.  Fluorescence study of domain structure and lipid interaction of human apolipoproteins E3 and E4.

Authors:  Chiharu Mizuguchi; Mami Hata; Padmaja Dhanasekaran; Margaret Nickel; Keiichiro Okuhira; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochim Biophys Acta       Date:  2014-12

Review 3.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

Review 4.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

5.  Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.

Authors:  Maria Katsarou; Efstratios Stratikos; Angeliki Chroni
Journal:  J Lipid Res       Date:  2018-10-11       Impact factor: 5.922

6.  Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4.

Authors:  Letta Argyri; Ioannis Dafnis; Theodossis A Theodossiou; Donald Gantz; Efstratios Stratikos; Angeliki Chroni
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

7.  The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific.

Authors:  Ioannis Dafnis; Letta Argyri; Marina Sagnou; Athina Tzinia; Effie C Tsilibary; Efstratios Stratikos; Angeliki Chroni
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

8.  Complement Factor H and Apolipoprotein E Participate in Regulation of Inflammation in THP-1 Macrophages.

Authors:  Eija Nissilä; Pipsa Hakala; Katarzyna Leskinen; Angela Roig; Shahan Syed; Kok P M Van Kessel; Jari Metso; Carla J C De Haas; Päivi Saavalainen; Seppo Meri; Angeliki Chroni; Jos A G Van Strijp; Katariina Öörni; Matti Jauhiainen; T Sakari Jokiranta; Karita Haapasalo
Journal:  Front Immunol       Date:  2018-11-21       Impact factor: 7.561

9.  A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate.

Authors:  Hitoshi Kodera; Yasuhide Mizutani; Satoshi Sugiyama; Toshio Miyata; Takashi Ehara; Akira Matsunaga; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2017-07-27

10.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.

Authors:  Megumu Fukunaga; Kiyotaka Nagahama; Michiko Aoki; Akira Shimizu; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.